Acute Lymphoblastic Leukemia (ALL)
Conditions
Interventions
Blinatumomab group:Infusion of Blinatumomab for 14 days
control:No
Sponsors
Division of Pediatric Blood Diseases Center State Key Laboratory of Experimental Hematology, Institute of Hematology, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
0.1 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. Aged 1 month to 18 years; 2. CD 19+ B-acute lymphoblastic leukemia; 3. According to CCCG-ALL2020 plan, they were divided into medium-risk group and high-risk group; 4. MRD >= 0.01% on day 46 of induction chemotherapy; 5. Comply with relevant guidelines of institutional Review Board, NCI and FDA, and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who currently have active liver or biliary disease (e.g., gilbert syndrome, asymptomatic gallstones, liver metastases, or stable chronic liver disease, as assessed by the treating physician); 2. Have a clinically relevant history of the central nervous system (CNS) or a disease such as epilepsy, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome or psychosis; patients with leukemia involving the central nervous system can be included; 3. Autoimmune disease or history of autoimmune disease that may involve the central nervous system; 4. Human immunodeficiency virus (HIV) positivity; 5. The diseases/infections that are active and uncontrolled as judged by the physician; 6. The guardian does not agree or cannot obtain the consent of the guardian.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MRD(Molecular Residual Disease); | — |
Countries
China
Contacts
Public ContactZhu Xiaofan
Division of Pediatric Blood Diseases Center State Key Laboratory of Experimental Hematology, Institute of Hematology, Chinese Academy of Medical Sciences
Outcome results
None listed